Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors
Cancer Research - United States
doi 10.1158/0008-5472.can-16-0026
Full Text
Open PDFAbstract
Available in full text
Date
August 22, 2016
Authors
Publisher
American Association for Cancer Research (AACR)